Worth Venture Partners’s Arcturus Therapeutics ARCT Stock Holding History

Worth Venture Partners’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-32,848	Closed	-$290K	–	93
2018 Q3	$290K	Buy	+32,848	New	+$274K	0.22%	61
2018 Q2	–	Sell	-33,184	Closed	-$183K	–	95
2018 Q1	$183K	Sell	33,184 -5,670	-15%	-$39.1K	0.16%	77
2017 Q4	$309K	Sell	38,854 -1	-0%	-$9	0.34%	61
2017 Q3	$275K	Hold	38,855	–	–	0.24%	71
2017 Q2	$305K	Buy	38,855 +10,210	+36%	+$82.2K	0.26%	71
2017 Q1	$229K	Buy	+28,645	New	+$265K	0.2%	90

Other funds holding ARCT

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Worth Venture Partners's ARCT Position: Q4 2018 in Review

Worth Venture Partners sold out of Arcturus Therapeutics (ARCT) in Q4 2018, closing a stake of 32,848 shares — an estimated $290K sold.

Worth Venture Partners first reported a position in ARCT in Q1 2017 and held it in 6 quarters. The position peaked at $309K in Q4 2017. 19 funds tracked by Wall St. Rank hold ARCT as of Q4 2018.

Worth Venture Partners reported no remaining Arcturus Therapeutics position as of Q4 2018 after selling out during the quarter.
Worth Venture Partners sold 32,848 Arcturus Therapeutics shares in Q4 2018, an estimated $290K.
Worth Venture Partners first reported a position in Arcturus Therapeutics in Q1 2017 and held it in 6 quarters.
Worth Venture Partners's Arcturus Therapeutics position peaked at $309K in Q4 2017.
19 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2018.

Based on Worth Venture Partners's 13F filing for Q4 2018, filed 15 Feb 2019.